Navigation Links
Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
Date:10/20/2013

BOSTON PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

About 3 to 5 percent of lung cancers harbor ALK gene abnormalities. The drug crizotinib (Xalkori), which blocks ALK protein kinase activity, was approved in August 2011 by the U.S. Food and Drug Administration for the treatment of patients who have these lung cancers. Although robust responses to crizotinib are observed for lung cancers harboring ALK gene abnormalities, the majority eventually become resistant to the effects of the drug. In many cases, resistance arises because of genetic mutations in ALK.

"Resistance to targeted therapies such as crizotinib is a major challenge when treating patients with cancer," said Tod Smeal, Ph.D., associate research fellow in the Oncology Research Unit at Pfizer Inc. in San Diego, Calif. "Our goal is to take advantage of everything we have learned about designing drugs that target kinases like ALK and the ways in which lung cancers become resistant to crizotinib to develop the best next-generation ALK inhibitor we can.

"Our preclinical studies suggest that we are making progress toward achieving our goal: PF-06463922 has potent ALK-inhibiting activity, it is capable of inhibiting all the crizotinib-resistant ALK mutants so far detected in patients, and it can efficiently access the brain. We are excited about these preclinical results and very hopeful that they will translate into meaningful responses in the clinic."

After carefully designing PF-06463922, Smeal and colleagues first showed in cell assays that it potently inhibited the activity of ALK and all eight of the mutant forms of ALK known to cause resistance to crizotinib
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
4. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
5. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
6. Killer infections targeted by hospital study
7. Lower risk of serious side-effects in trials of new targeted drugs
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
10. Deadly witch hunts targeted by grassroots womens groups
11. Large lung cancer study shows potential for more targeted therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... For PASCHA Chocolate, less is more. ... the robust flavor of the cacao bean bursts through ... is free from peanuts, nuts, dairy, soy, eggs, fish, ... 6th- 8th at Expo West., ,    NEW PASCHA ... broken new ground with their New PASCHA Make Me ...
(Date:3/5/2015)... Minn. (PRWEB) March 05, 2015 ... invites healthcare organizations to participate in its 2015 ... data from executive and director-level positions, and the ... , Last year’s report featured data on 60 ... independent children’s healthcare organizations and 7 subsidiary children’s ...
(Date:3/5/2015)... March 05, 2015 Leading nutritional supplement ... week’s Arnold Sports Festival and Arnold Fitness EXPO ... Metabolic Nutrition will host a display booth featuring free ... E.S.P. and its highly-popular, class-leading fat burner Synedrex. The ... unique recipes that utilize its top-of-the-line supplements and miniature ...
(Date:3/5/2015)... Indialantic, FL (PRWEB) March 05, 2015 ... sports nutrition products, is pleased to offer reformulated Millennium ... official website, Millennium 500 is a German grade creatine ... muscle hydration, promote muscle recovery, and aid with overall ... occurring compound that acts as a reserve energy source ...
(Date:3/5/2015)... Jordan Valley Medical Center is now utilizing ... for sudden cardiac arrest. When a patient wears this ... any life-threatening abnormalities. If an abnormal heart rhythm is ... a treatment shock to restore normal rhythm to the ... Medical Center and the Heart and Lung Institute of ...
Breaking Medicine News(10 mins):Health News:PASCHA Allergen Free Organic Chocolate to Appear at Natural Products Expo West March 6-8, 2015 2Health News:Participation Is Now Open For INTEGRATED Healthcare Strategies 2015 Children’s Hospitals Executive Compensation Survey 2Health News:Metabolic Nutrition Exhibiting at 2015 Arnold Sports Festival and Fitness EXPO This Week 2Health News:Nutrition Leaders Offers Reformulated Millennium 500 German Grade Creatine 2Health News:New Technology Behind LifeVest® Wearable Defibrillator Saves the Life of Utah Man in Cardiac Arrest 2Health News:New Technology Behind LifeVest® Wearable Defibrillator Saves the Life of Utah Man in Cardiac Arrest 3
... study conducted by researchers say it is a misconception ... older or housebound people.// ,Researchers examined 150 ... levels of vitamin D. Among the participants, all African-American, ... D deficiencies, as were all patients younger than 30. ...
... A pitch-black room may be the healthiest environment for your ... at night // may put children at risk for ... to disrupt the circadian rhythm and suppress the production of ... been shown to protect DNA from oxidative damage. Once damaged, ...
... study shows sinusitis in asthma patients tends to be ... suggest patients // can have dramatic improvement in symptoms ... is used. ,In the study patients with asthma ... polyps, olfactory dysfunction, and nasal congestion compared to patients ...
... new study shows moderate consumption of alcohol may cut ... arteries.// Researchers evaluated 225 men after they had undergone ... open blocked arteries with a stent. Less traumatic than ... cause inflammation resulting in renarrowing of the artery, usually ...
... study researchers say the antidepressant duloxetine, also known ... fibromyalgia in women . Duloxetine works by stopping ... of the brain’s neurotransmitters that are linked to ... that is characterized by body pain, muscle tenderness, ...
... cluster of risk factors known as metabolic syndrome is ... risk factors. // ,Metabolic syndrome has been ... coronary heart disease. Metabolic syndrome includes looking at factors ... has two different definitions including one by the National ...
Cached Medicine News:
(Date:3/5/2015)... 2015  Celsion Corporation (NASDAQ: CLSN ... a conference call to discuss year-end 2014 financial ... programs for ThermoDox®, its proprietary heat-activated liposomal encapsulation ... TheraPlas™ and TheraSilence™, in immunotherapy and RNA delivery ... 2015. To participate in the call, interested parties ...
(Date:3/5/2015)... , March 5, 2015 - ... agency ( http://www.epa.eu ) - Hitachi ... della nuova generazione di OASIS* all,ECR 2015. Si tratta ... alto campo da 1.2 T che migliora la capacità ... traguardo nell,attenzione al comfort del paziente. Le nuove funzionalità ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/gl7m98/japan_pharma ) ... Outlook 2015: Year to Watch out for Authorized Generics ... their offering. The new pricing system ... -2014 (Annexure 1) is a game changer initiative. It ... innovator. The most of the companies are revalidating their ...
Breaking Medicine Technology:Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 2Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 3Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 4Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3
... Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) today announced ... on Tuesday, November 1, 2011 at 4:30 p.m. Eastern Time/1:30 ... a business and financial update and review third quarter 2011 ... may be accessed from the Investors section of the Jazz ...
... Genprex, Inc. announced today that it will be presenting ... in San Francisco.   Greg Heinlein , Chief Operating and Financial ... Investor Forum , on October 25 starting at 11 a.m. PDT ... will be made available on the company,s website under the News ...
Cached Medicine Technology:Genprex Presenting at 10th Annual BIO Investor Forum 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: